Review
Nature Reviews Drug Discovery 5, 147-159 (February 2006) | doi:10.1038/nrd1957
Antibody targeted drugs as cancer therapeutics
David Schrama1, Ralph A. Reisfeld2 & Jürgen C. Becker1 About the authors
Abstract
Treatment of cancer is a double-edged sword: it should be as aggressive as possible to completely destroy the tumour, but it is precisely this aggressiveness which often causes severe side effects — a reason why some promising therapeutics can not be applied systemically. In addition, therapeutics such as cytokines that physiologically function in a para- or autocrine fashion require a locally enhanced level to exert their effect appropriately. An elegant way to accumulate therapeutic agents at the tumour site is their conjugation/fusion to tumour-specific antibodies. Here, we discuss recent preclinical and clinical data for antibody–drug conjugates and fusion proteins with a special focus on drug components that exert their antitumour effects through normal biological processes.
- View At a Glance
Author affiliations
- University of Wuerzburg, Dermatology, 97080 Wuerzburg, Germany
- The Scripps Research Institute, La Jolla, California 92037, USA
Published online 20 January 2006
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Two heads are better than oneNature Biotechnology News and Views (01 Nov 2007)
The rollercoaster ride to anti-cancer antibodiesNature Biotechnology Research News (01 May 2003)
RESEARCH
Arming antibodies: prospects and challenges for immunoconjugatesNature Biotechnology Research (01 Sep 2005)
See all 3 matches for Research

